जब मॉइस्चराइज़ेशन पर्याप्त न हो: एटोपिक डर्मेटाइटिस का प्रथम-पंक्ति उपचार

References

DOI: 10.1016/j.anai.2023.11.009

• In patients with uncontrolled atopic dermatitis refractory to moisturization alone, the JTF panel recommends addition of a topical corticosteroid over no topical corticosteroid (strong recommendation, high-certainty evidence).
• In patients aged 3 months or older with uncontrolled atopic dermatitis refractory to moisturization alone, the JTF panel recommends addition of a topical calcineurin inhibitor (pimecrolimus, tacrolimus) over no added topical calcineurin inhibitor (strong recommendation, high-certainty evidence).
• In patients with uncontrolled atopic dermatitis using mid-to high-potency topical treatments (tacrolimus, topical corticosteroid US classes 1-5), the JTF panel suggests applying the medication once per day over twice per day (conditional recommendation, moderate certainty evidence).
• Avoid high-potency (classes 1 and 2) TCS for prolonged periods of time (>4 weeks) and limit its use on sensitive areas (face, folds, groin)—rare instances of atrophy, telangiectasia, and striae may be more likely to occur in these areas.
• The available RCTs systematically reviewed (topical and systemic NMAs) and AD experts typically expect response to mid- or high-potency topical therapy within 2 to 6 weeks.